Zhongsheng Pharmaceutical Subsidiary Receives Clinical Trial Approval for New Indication of Class 1 Innovative Drug RAY1225 Injection
January 26, 2026
Source: drugdu
28
Beijing Business Today News – On the evening of January 23, Zhongsheng Pharmaceutical (002317) released an announcement stating that its holding subsidiary, Guangdong Zhongsheng Ruichuang Biological Technology Co., Ltd. (hereinafter referred to as "Zhongsheng Ruichuang"), has received approval from the National Medical Products Administration (NMPA) for a Phase III clinical trial of its self-developed Class 1 innovative peptide drug, RAY1225 Injection. The approval, confirmed via the "Drug Clinical Trial Approval Notice," covers a new indication: the treatment of "obesity comorbid with obstructive sleep apnea (OSA)."
According to the announcement, RAY1225 Injection is an innovatively structured peptide drug with global independent intellectual property rights developed by Zhongsheng Ruichuang. It functions as a dual GLP-1 (Glucagon-like peptide-1) receptor and GIP (Glucose-dependent insulinotropic polypeptide) receptor agonist. Benefiting from its superior pharmacokinetic profile, the drug demonstrates ultra-long-acting potential, supporting a convenient once-every-two-weeks dosing schedule.
https://finance.eastmoney.com/a/202601233629301734.html
Copyright©2026 Ddu. All rights reserved.
Read more on
- Flunotinib maleate receives Breakthrough Therapy Designation January 26, 2026
- The National Medical Products Administration (NMPA) has conditionally approved the marketing of ribevirtadalafil injection. January 26, 2026
- Revenue Up 72.57%, HIV Innovative Drug Sales Surge 90.34% January 26, 2026
- Loxoprofen Sodium Gel Patch Receives Drug Registration Certificate January 26, 2026
- ASC30 Completes First Dosing in US Phase II Clinical Trial for Diabetes Treatment On January 26, Ascletis Pharma (01672) announced that it had completed dosing of the first subjects in its Phase II US study of the oral small molecule GLP-1R agonist ASC30 for the treatment of diabetes. Top-line data from the study are expected to be available in the third quarter of 2026. A 13-week study in obese or overweight subjects showed that ASC30 resulted in a placebo-adjusted weight loss of up to 7.7%, with better gastrointestinal tolerability and no liver safety signals observed. The study enrolled 125 obese subjects or overweight subjects with at least one weight-related comorbidity. At the primary endpoint of week 13, once-daily doses of ASC30 tablets at 20 mg, 40 mg, and 60 mg resulted in weight loss of 5.4%, 7.0%, and 7.7%, respectively, which were statistically significant and clinically meaningful. The overall discontinuation rate due to adverse events was 4.8%. ASC30 is the first small molecule GLP-1R fully biased agonist currently in clinical trials, and is indicated for the treatment of obesity, diabetes and other metabolic diseases. 网址：https January 26, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
